Visus Therapeutics is a clinical-stage company in pursuit of developing the the world's first presbyopia-correcting eye drop with the potential to last at least eight hours.

With offices in Seattle, Washington, and Orange County, California, our lead clinical candidate is BRIMOCHOL™ (carbachol + brimonidine tartrate), an eye drop being evaluated to correct the loss of near vision associated with presbyopia. In parallel, Visus Therapeutics is focused on advancing its pipeline of early-stage ophthalmic product candidates.

Media contact: